All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA
Professor Marek Trněný
Charles University Hospital, Prague, CZ
Topic: Will 8xR-CHOP followed by rituximab maintenance become the standard of care for elderly patients?
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
AUGMENT: Is the combination of lenalidomide & rituximab efficacious in elderly patients with iNHL?
Marek Trněný gives an overview of the AUGMENT study design and results of the post-hoc analysis of the data in the elderly population.
Results from a phase II study: brentuximab plus DTIC is a good choice in elderly, front-line HL patients
The results of this study ought to serve as a template and give rise to additional studies of novel induction regimens for elderly HL patients.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox